Fulgent Oncology is part of Fulgent Genetics, a genetic testing company founded in 2011. We were the first clinical laboratory in the U.S. to offer copy number variation (CNV) detection using NGS technology, and we've continued to pursue excellence in precision medicine ever since.
We expanded our capabilities in 2021 through the acquisition of CSI Laboratories, a leader in anatomic pathology and hematology on the East coast with more than 25 years of experience. In 2022, we acquired Inform Diagnostics, a leading anatomic pathology and hematology laboratory on the West coast. As our companies have come together, we've harnessed our collective expertise to create a unique, comprehensive offering.